MediciNova Announces Acceptance of Abstract Regarding MN-166 ( ibudilast ) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS ( Northeast Amyotrophic Lateral Sclerosis Consortium ) Meeting - MediciNova ( NASDAQ:MNOV )

2 weeks ago

LA JOLLA, Calif., Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV and the Standard Market of the Tokyo Stock Exchange ( Code Number: 4875 ) , today announced that an abstract was accepted for presentation regarding a ...

Ticker	Sentiment	Impact
MNOV	Neutral	33 %